Demand for Graft Versus Host Disease Treatment in USA

Future Market Insights

Key Insight

The demand for graft versus host disease treatment in USA is projected to grow from USD 1.2 billion in 2026 to USD 2.1 billion by 2036, at a CAGR of 5.9%. Monoclonal antibodies will dominate with a 42.0% market share, while chronic graft versus host disease (cgvhd) will lead the disease type segment with a 58.0% share.

December 23, 2025

Anurag Sharma

250 Pages

Cite this Report

Demand for Graft Versus Host Disease Treatment in USA

https://www.futuremarketinsights.com/reports/united-states-graft-versus-host-disease-treatment-market

License

Starting at US$ 5000

Buy Now

Summary ToC Companies

Key Players

Bristol-Myers Squibb
Incyte Corporation
Mallinckrodt Pharmaceuticals
Novartis
The Vanguard Group

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Demand for Graft Versus Host Disease Treatment in USA

Key Players

Similar Industry Reports